Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. This will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Investors can access the listen-only webcast on the company's website, with a replay available for approximately 30 days.

Allogene Therapeutics, Inc. announced the appointment of Zachary Roberts, M.D., Ph.D. as its new President and Chief Executive Officer, effective July 1, 2026. Dr. Roberts, currently Executive Vice President, Research and Development, and Chief Medical Officer, will also join the Board of Directors. He replaces David Chang, M.D., Ph.D., who will step down from his executive roles on June 30, 2026, but will remain on the Board as a non-employee director. Dr. Roberts' compensation package includes an annual base salary of $680,000, a 60% target performance cash incentive, and equity awards.

Allogene Therapeutics announced a leadership transition, with Dr. David Chang stepping down as President and Chief Executive Officer on June 30, 2026, after eight years. Dr. Chang, a co-founder, will continue to serve on the Board of Directors. Zachary Roberts, currently Executive Vice President, Research & Development and Chief Medical Officer, has been unanimously elected to succeed Dr. Chang as President and CEO, effective July 1, 2026, and will also join the Board.

Allogene Therapeutics, a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences. The company will present at the TD Cowen 7th Annual Oncology Innovation Summit on May 26, the Jefferies Global Healthcare Conference on June 3, and the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 9. Webcasts of the presentations will be available on Allogene's investor relations website.

Allogene Therapeutics reported a net loss of $42.6 million for the first quarter of 2026, a notable improvement from a $59.7 million net loss in the same period last year. Research and development expenses significantly decreased by 36% to $32.0 million. The company bolstered its financial position by raising $20.7 million through an at-the-market (ATM) offering and receiving $23.7 million from an escrow release. As of March 31, 2026, Allogene Therapeutics held $266.9 million in cash, cash equivalents, and investments, which, combined with proceeds from an April 2026 public offering, are expected to fund operations for at least the next 12 months.

Allogene Therapeutics terminated its Exclusive License Agreement with Overland Therapeutics, effective May 12, 2026, which previously granted Overland rights to develop and commercialize four allogeneic CAR T cell therapies in Greater China, Taiwan, South Korea, and Singapore. As part of the termination, Allogene surrendered a portion of its equity in Overland for no consideration, reducing its stake to approximately 3%. Concurrently, Allogene reported a Q1 2026 net loss of $42.6 million and provided positive clinical updates for its ALPHA3 trial (cema-cel) and RESOLUTION trial (ALLO-329), alongside an extended cash runway into Q1 2029 due to a $200.4 million public offering.

Allogene Therapeutics reported encouraging interim futility analysis results from its pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL, showing 58.3% MRD clearance in the cema-cel arm with a favorable safety profile, supporting its potential as an outpatient therapy. The company also provided updates on its Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease, noting early signs of clinical activity and favorable tolerability. Financially, Allogene ended Q1 2026 with $266.9 million in cash and extended its cash runway into Q1 2029 following a $200.4 million public offering in April.

Allogene Therapeutics, Inc. announced it will report its first quarter 2026 financial results and provide a business update on May 13, 2026, after the close of the market. This will be followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET. A listen-only webcast will be available on the company's website, with registration required for those wishing to ask questions.

Allogene Therapeutics will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026. Key proposals include the election of three directors, advisory votes on executive compensation and its frequency, and a proposal to increase authorized common stock from 400 million to 800 million shares. The Board of Directors will also be reduced from eleven to ten members, with Mr. Todd Sisitsky not standing for re-election. The company highlighted 2025 progress in its cema-cel, ALLO-316, and ALLO-329 programs, alongside operational and cost realignment initiatives.

Allogene Therapeutics announced regulatory clearance to expand its pivotal Phase 2 ALPHA3 study for cemacabtagene ansegedleucel (cema-cel) in first-line large B-cell lymphoma (LBCL) to South Korea and Australia. This expansion adds over 20 new global sites, bringing the total to over 80, and is expected to support continued enrollment and global development. The company recently reported interim futility analysis findings showing cema-cel achieved 58.3% minimal residual disease (MRD) clearance compared to 16.7% in the standard-of-care arm, with a favorable tolerability profile.